argenx SE (ARGX) PT Raised to $725 at Piper Sandler Following New Neurologist Surveys

Piper Sandler analyst Allison M. Bratzel raised the price target on argenx SE (NASDAQ: ARGX) to $725.00 (from $620.00) while maintaining a Overweight rating.

The analyst said: "Remain Overweight rated on ARGX shares and increasing our estimates for the Vyvgart franchise in both gMG and CIDP following new neurologist surveys on the gMG space and our back-of-the-envelope math on various CIDP launch scenarios. Bottom line, we are increasing our WW Vyvgart estimates to $679M, $2,128M, and $3,268M for Q424, FY24, and FY25, respectively (previously $631M, $2,080M, and $3,078M), and increasing our price target from $620 to $725, as we think continued commercial outperformance will continue to drive the stock higher in FY25, with the pipeline beyond MG/CIDP serving as a source of additional upside. ARGX remains a top pick and we remain buyers here."

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recover
• Cineverse (CNVS) PT Raised to $14 at Benchmark on Revenue, Earnings Beat